Dexcom, Inc. (DXCM, Financial) experienced a significant stock movement with a 5.02% increase in its share price. The stock is currently trading at $73.84 per share, with a trading volume of 1.60357 million shares, representing a turnover rate of 0.41% and a price fluctuation amplitude of 6.52%.
The company's recent financial report reveals a revenue of $994 million and a net profit of $135 million, resulting in earnings per share (EPS) of $0.34. Dexcom's gross profit reached $594 million, with a price-to-earnings (P/E) ratio of 44.59. In terms of analyst ratings, 78% of the 27 analysts covering the stock have issued a buy recommendation, while 22% suggest holding, and none recommend selling.
Within the medical device industry, which saw an overall increase of 0.39%, Dexcom stands out. Notably, other related stocks such as Dih Holdings Us Inc C/Wts 20/04/2028 (To Pur Com), Zomedica Corp., and Bluejay Diagnostics, Inc. showed considerable gains. Bluejay Diagnostics, Inc., Nuwellis, Inc., and Tivic Health Systems, Inc. were particularly active, with turnover rates of 223.96%, 40.87%, and 24.94%, respectively. Bluejay Diagnostics, Inc., Biosig Technologies, Inc., and Nevro Corp. had significant price volatility, with amplitudes of 42.36%, 37.67%, and 30.57%.
Dexcom specializes in developing and commercializing continuous glucose monitoring (CGM) systems for diabetes patients. Their CGM systems serve as an alternative to traditional glucose meters, and the company is advancing these systems to integrate with insulin pumps for automated insulin delivery.
